Promising Outcome From Collaboration With Dundee Sustainable Technologies
Highlights
GlassLock Process™ testing on high-grade underground sulphide material at Beartrack-Arnett boosted the concentrate gold grade 31% and cut the arsenic content by 99% with almost no loss in gold.
DST's GlassLock Process has been successfully tested globally and used at an industrial scale at the Tsumeb smelter facility in Namibia.
3,900-meter core drilling program will be kicked off later this year to continue to test and expand on the high-grade underground potential at Beartrack-Arnett.
The DST work was undertaken subsequent to Dundee Corporation's purchase of a strategic stake in Revival Gold (see Revival Gold news release dated February 19th, 2025) and followed up a previously reported flotation testing program on a 4.6 g/T gold composite from the Joss deposit that yielded a flotation concentrate grading 50 g/T gold, 23% sulphide sulphur and 13.5% arsenic (see Revival Gold news release dated September 6th, 2023). DST developed a similar arsenopyrite-rich concentrate from Joss samples (50.3 g/T gold, 23.6% sulphide sulphur, 13.7% arsenic) and following their GlassLock Process™ the concentrate graded 66.1 g/T gold (a 31% increase), 17.9% sulphide sulphur (a 24% reduction), and 0.19% arsenic (a 99% reduction). No measurable gold was lost during the GlassLock Process™. The primary biproduct from the GlassLock Process™ is a stable, insoluble, arsenic-rich glass characterized as non-toxic using Environmental Protection Agency's Method 1311 Toxicity Characteristic Leaching Procedure.
'DST's Glasslock Process™ offers Revival Gold the opportunity to produce a direct-to-smelter saleable gold concentrate from a potential second phase underground sulphide operation following the planned open pit heap leach phase at Beartrack-Arnett,' said Hugh Agro, Revival Gold President & CEO. 'A 3,900-meter exploration drilling program will be initiated later this year as we continue to test and expand Beartrack-Arnett's high-grade underground potential,' added Agro.
ARTICLE CONTINUES BELOW
'One of the key attractions for Dundee Corporation in getting involved with Revival Gold earlier this year was the potential for our subsidiary business, DST, to help unlock additional value from Revival Gold's high-grade sulphide material,' observed Jonathan Goodman, President & CEO, Dundee Corporation. 'DST is expected to play a big role in the future of gold processing with GlassLock™ already having been successfully tested on projects in Canada, the United States and Africa and implemented on an industrial–scale to stabilize arsenic-bearing feed materials at Dundee Precious Metal Inc.'s Tsumeb smelter facility in Namibia,' added Goodman.
Results from Revival Gold's DST metallurgical testing will be presented by the Company's, Vice President, Engineering & Development, John Meyer, at the upcoming Nevada Mineral Processors Division annual meeting taking place August 20-22, 2025, in Reno, Nevada.
Qualified Persons
Technical information included in this news release was reviewed and approved by Mr. John Meyer, P.Eng., a QP and Vice President, Engineering and Development for the Company.
About Dundee Corporation
Dundee Corporation is a public Canadian independent holding company, listed on the Toronto Stock Exchange under the symbol 'DC.A'. Through its operating subsidiaries, including Dundee Sustainable Technologies, Dundee Corporation is an active investor focused on delivering long-term, sustainable value as a trusted partner in the mining sector with more than 30 years of experience making accretive mining investments.
About Revival Gold Inc.
Revival Gold is one of the largest, pure gold mine developers in the United States. The Company is advancing development of the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol 'RVG' and trades on the OTCQX Market under the ticker symbol 'RVLGF'. The Company is headquartered in Toronto, Canada, with its exploration and development office located in Salmon, Idaho.
For further information, please contact:
Hugh Agro, President & CEO or Lisa Ross, Vice President & CFO
Telephone: (416) 366-4100 or Email: info@revival-gold.com
Cautionary Statement
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation and 'forward-looking statements' within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (collectively, 'forward-looking statements'). Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company's future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as 'believes', 'anticipates', 'expects', 'estimates', 'may', 'could', 'would', 'will', or 'plan'. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to the Company, the Company provides no assurance that actual results will meet management's expectations. Risks, uncertainties, and other factors involved with forward-looking statements could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to: statements with respect to the Company's exploration, metallurgy and development activities at Beartrack-Arnett, the goals and expected outcomes of the planned drill program at Beartrack-Arnett, the ability of DST's Glasslock Process™ to produce a direct-to-smelter saleable gold concentrate, and the expectation the Mercur will reach production and the timing thereof.
Forward-looking statements and information involve significant known and unknown risks and uncertainties, should not be read as guarantees of future performance or results and will not necessarily be accurate indicators of whether or not such results will be achieved. A number of factors could cause actual results to differ materially from the results expressed or implied by such forward-looking statements or information, including, but not limited to: the Company's ability to finance the development of its mineral properties; uncertainty as to whether there will ever be production at the Company's mineral exploration and development properties; risks related to the Company's ability to commence production at the projects and generate material revenues or obtain adequate financing for its planned exploration and development activities; uncertainties relating to the assumptions underlying resource and reserve estimates; mining and development risks, including risks related to infrastructure, accidents, equipment breakdowns, labour disputes, bad weather, non-compliance with environmental and permit requirements or other unanticipated difficulties with or interruptions in development, construction or production; the geology, grade and continuity of the Company's mineral deposits; the uncertainties involving success of exploration, development and mining activities; permitting timelines; government regulation of mining operations; environmental risks; unanticipated reclamation expenses; prices for energy inputs, labour, materials, supplies and services; uncertainties involved in the interpretation of drilling results and geological tests and the estimation of reserves and resources; unexpected cost increases in estimated capital and operating costs; the need to obtain permits and government approvals; material adverse changes, unexpected changes in laws, rules or regulations, or their enforcement by applicable authorities; the failure of parties to contracts with the company to perform as agreed; social or labour unrest; changes in commodity prices; and the failure of exploration programs or studies to deliver anticipated results or results that would justify and support continued exploration, studies, development or operations. For a more detailed discussion of such risks and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, refer to other risks and uncertainties disclosed in the Company's public filings with Canadian securities regulators, including its most recent annual information form and management's discussion and analysis, available at www.sedarplus.ca. The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
a few seconds ago
- Cision Canada
Medtronic reports first quarter fiscal 2026 financial results
11 th quarter in a row of mid-single digit organic revenue growth; Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8% organic GAAP diluted EPS of $0.81 increased 1%; non-GAAP diluted EPS of $1.26 increased 2% Company raises FY26 EPS guidance; reiterates FY26 organic revenue growth guidance Cardiac Ablation Solutions revenue increased nearly 50%, including 72% in the US, on strength of pulsed field ablation (PFA) products U.S. Centers for Medicare & Medicaid Services (CMS) posted proposed National Coverage Determination (NCD) for the Symplicity Spyral™ system for hypertension; final NCD expected on or before October 8, 2025 Received CE Mark for LigaSure™ RAS vessel-sealing technology on Hugo™ robotic-assisted surgery (RAS) system "We delivered another consistent quarter of mid-single digit organic revenue growth, with broad strength from several innovative product categories, including Pulsed Field Ablation, Transcatheter Valves, Neuromodulation, Diabetes, and Leadless Pacing," said Geoff Martha, Medtronic chairman and chief executive officer. "We're confident and well positioned to accelerate our revenue growth in the second half of our fiscal year, as we make meaningful progress on our major growth drivers." Financial Results Medtronic reported Q1 worldwide revenue of $8.578 billion and adjusted revenue of $8.539 billion, an increase of 8.4% as reported and 4.8% on an organic basis. The organic revenue growth comparison excludes: Other revenue of $72 million in the current year and -$52 million in the prior year; and Foreign currency benefit of $159 million on the remaining segments. Q1 revenue by segment included: Cardiovascular Portfolio revenue of $3.285 billion increased 9.3% as reported and 7.0% organic, with a high-single digit increase in Cardiac Rhythm & Heart Failure, mid-single digit increase in Structural Heart & Aortic, and low-single digit increase in Coronary & Peripheral Vascular, all on an organic basis; Neuroscience Portfolio revenue of $2.416 billion increased 4.3% reported and 3.1% organic, with a high-single digit increase in Neuromodulation and mid-single digit increase in Cranial & Spinal Technologies, offset by a low-single digit decrease in Specialty Therapies, all on an organic basis; Medical Surgical Portfolio revenue of $2.083 billion grew 4.4% as reported and 2.4% organic, with low-single digit organic growth in both Surgical & Endoscopy and Acute Care & Monitoring; and Diabetes business revenue of $721 million increased 11.5% as reported and 7.9% organic. Q1 GAAP operating profit and operating margin were $1.445 billion and 16.8%, respectively, increases of 13% and 70 basis points, respectively. As detailed in the financial schedules included at the end of the release, Q1 non-GAAP operating profit and operating margin were $2.016 billion and 23.6%, respectively, an increase of 3% and decrease of 80 basis points, respectively. Q1 GAAP net income and diluted earnings per share (EPS) were $1.040 billion and $0.81, respectively, flat and an increase of 1%, respectively. As detailed in the financial schedules included at the end of this release, Q1 non-GAAP net income and non-GAAP diluted EPS were $1.626 billion and $1.26, respectively, both increases of 2%. Non-GAAP diluted EPS had no impact from foreign currency translation. Guidance The company today reiterated its FY26 revenue growth and raised its FY26 EPS guidance. The company continues to expect FY26 organic revenue growth of approximately 5%. The organic revenue growth guidance excludes the impact of foreign currency exchange and revenue reported as Other. Including Other revenue and the impact of foreign currency exchange, assuming recent foreign currency exchange rates, FY26 revenue growth on a reported basis would be in the range of 6.5% to 6.8%. Excluding the potential impact from tariffs, Medtronic now expects underlying FY26 diluted non-GAAP EPS growth to be approximately 4.5% versus the prior guidance of approximately 4%. Including the reduced potential impact from tariffs of approximately $185 million versus the prior range of approximately $200 million to $350 million, Medtronic is raising its FY26 diluted non-GAAP EPS guidance to the new range of $5.60 to $5.66 versus the prior range of $5.50 to $5.60. "As a result of our Q1 EPS outperformance and improved tariff impact assumption, we are raising our full year EPS guidance," said Thierry Piéton, Medtronic chief financial officer. "Our confidence continues to increase as we advance our revenue growth drivers and execute on efficiencies in manufacturing, supply chain, and operating expenses to drive earnings growth, and increase our growth investments in R&D, sales, and marketing, all with a deliberate focus on creating long-term shareholder value." Video Webcast Information Medtronic will host a video webcast today, August 19, at 8:00 a.m. EDT (7:00 a.m. CDT) to provide information about its business for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Quarterly Earnings icon at and this earnings release will be archived at Within 24 hours of the webcast, a replay of the webcast and transcript of the company's prepared remarks will be available by clicking on the Past Events and Presentations link under the News & Events drop-down at Financial Schedules and Earnings Presentation The first quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Quarterly Earnings link at To view a printable PDF of the financial schedules and non-GAAP reconciliations, click here. To view the first quarter earnings presentation, click here. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit and follow on LinkedIn. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, material acquisition and divestiture transactions, general economic conditions, and other risks and uncertainties described in the company's periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release, including to reflect future events or circumstances. NON-GAAP FINANCIAL MEASURES This press release contains financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered "non-GAAP" financial measures under applicable SEC rules and regulations. References to quarterly or annual figures increasing, decreasing or remaining flat are in comparison to fiscal year 2025, and references to sequential changes are in comparison to the prior fiscal quarter. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis. Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company's underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company's consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release. Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, as well as significant acquisitions, divestitures, or other significant discrete items. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance. Contacts: Erika Winkels Public Relations +1-763-526-8478 Ryan Weispfenning Investor Relations +1-763-505-4626 MEDTRONIC PLC WORLD WIDE REVENUE (1) (Unaudited) FIRST QUARTER REPORTED ORGANIC (in millions) FY26 FY25 Growth Currency Impact (4) FY26 (5) FY25 (5) Growth Cardiovascular $ 3,285 $ 3,007 9.3 % $ 68 $ 3,217 $ 3,007 7.0 % Cardiac Rhythm & Heart Failure 1,712 1,535 11.5 37 1,676 1,535 9.1 Structural Heart & Aortic 930 856 8.7 22 908 856 6.1 Coronary & Peripheral Vascular 643 616 4.5 10 633 616 2.9 Neuroscience 2,416 2,317 4.3 27 2,389 2,317 3.1 Cranial & Spinal Technologies 1,211 1,147 5.5 12 1,199 1,147 4.5 Specialty Therapies 702 713 (1.5) 9 694 713 (2.7) Neuromodulation 504 457 10.2 7 496 457 8.6 Medical Surgical 2,083 1,996 4.4 40 2,044 1,996 2.4 Surgical & Endoscopy 1,612 1,544 4.4 32 1,580 1,544 2.3 Acute Care & Monitoring 471 452 4.3 8 464 452 2.6 Diabetes 721 647 11.5 23 698 647 7.9 Total Reportable Segments 8,506 7,967 6.8 159 8,347 7,967 4.8 Other (2) 72 (52) NM (3) 3 — — — TOTAL $ 8,578 $ 7,915 8.4 % $ 162 $ 8,347 $ 7,967 4.8 % (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (2) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested and adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015. (3) Not meaningful (NM) (4) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. (5) The three months ended July 25, 2025 includes $231 million of revenue adjustments, including $33 million of inorganic revenue for the transition activity noted in (2), $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (2), and $159 million of favorable currency impact on the remaining segments. The three months ended July 26, 2024 excludes $52 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2) and $38 million of inorganic revenue related to the transition activity noted in (2). (1) U.S. includes the United States and U.S. territories. (2) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (3) Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested. MEDTRONIC PLC INTERNATIONAL REVENUE (1) (Unaudited) FIRST QUARTER REPORTED ORGANIC (in millions) FY26 FY25 Growth Currency Impact (4) FY26 (5) FY25 (5) Growth Cardiovascular $ 1,806 $ 1,604 12.6 % $ 68 $ 1,737 $ 1,604 8.3 % Cardiac Rhythm & Heart Failure 878 769 14.2 37 842 769 9.4 Structural Heart & Aortic 558 487 14.6 22 536 487 10.1 Coronary & Peripheral Vascular 369 347 6.3 10 359 347 3.4 Neuroscience 792 752 5.4 27 765 752 1.7 Cranial & Spinal Technologies 320 292 9.7 12 309 292 5.7 Specialty Therapies 309 314 (1.7) 9 301 314 (4.4) Neuromodulation 163 146 11.9 7 156 146 6.9 Medical Surgical 1,199 1,115 7.5 40 1,159 1,115 4.0 Surgical & Endoscopy 990 915 8.3 32 958 915 4.8 Acute Care & Monitoring 209 200 4.1 8 201 200 0.2 Diabetes 504 432 16.7 23 481 432 11.4 Total Reportable Segments 4,301 3,903 10.2 159 4,142 3,903 6.1 Other (2) 53 (70) NM (3) 3 — — — TOTAL $ 4,354 $ 3,832 13.6 % $ 162 $ 4,142 $ 3,903 6.1 % (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (2) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested and adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015. (3) Not meaningful (NM) (4) The currency impact to revenue measures the change in revenue between current and prior year periods using constant exchange rates. (5) The three months ended July 25, 2025 includes $212 million of revenue adjustments, including $14 million of inorganic revenue for the transition activity noted in (2), $39 million reduction in the Italian payback accruals due to changes in estimates further described in note (2), and $159 million of favorable currency impact on the remaining segments. The three months ended July 26, 2024 excludes $70 million of revenue adjustments related to $90 million of incremental Italian payback accruals further described in note (2) and $19 million of inorganic revenue related to the transition activity noted in (2). The data in the schedule above has been intentionally rounded to the nearest million. MEDTRONIC PLC GAAP TO NON-GAAP RECONCILIATIONS (1) (Unaudited) Three months ended July 25, 2025 (in millions, except per share data) Net Sales Cost of Products Sold Gross Margin Percent Operating Profit Operating Profit Percent Income Before Income Taxes Net Income attributable to Medtronic Diluted EPS Effective Tax Rate GAAP $ 8,578 $ 3,001 65.0 % $ 1,445 16.8 % $ 1,302 $ 1,040 $ 0.81 19.6 % Non-GAAP Adjustments: Amortization of intangible assets (2) — — — 459 5.5 459 374 0.29 18.5 Restructuring and associated costs (3) — (16) 0.1 67 0.8 67 51 0.04 22.4 Acquisition and divestiture-related items (4) — (7) — 58 0.7 58 48 0.04 17.2 Certain litigation charges, net — — — 27 0.3 27 21 0.02 22.2 (Gain)/loss on minority investments (5) — — — — — 113 107 0.08 6.2 Other (6) (39) — (0.2) (39) (0.5) (39) (30) (0.02) 20.5 Certain tax adjustments, net — — — — — — 16 0.01 — Non-GAAP $ 8,539 $ 2,979 65.1 % $ 2,016 23.6 % $ 1,987 $ 1,626 $ 1.26 17.8 % Currency impact (159) (46) (0.1) (10) 0.3 — Currency Adjusted $ 8,380 $ 2,933 65.0 % $ 2,006 23.9 % $ 1.26 Three months ended July 26, 2024 (in millions, except per share data) Net Sales Cost of Products Sold Gross Margin Percent Operating Profit Operating Profit Percent Income Before Income Taxes Net Income attributable to Medtronic Diluted EPS Effective Tax Rate GAAP $ 7,915 $ 2,761 65.1 % $ 1,278 16.1 % $ 1,268 $ 1,042 $ 0.80 17.4 % Non-GAAP Adjustments: Amortization of intangible assets — — — 414 5.1 414 340 0.26 18.1 Restructuring and associated costs (3) — (9) 0.1 62 0.8 62 51 0.04 19.4 Acquisition and divestiture-related items (4) — (10) 0.1 12 0.1 12 11 0.01 8.3 Certain litigation charges, net — — — 81 1.0 81 68 0.05 16.0 (Gain)/loss on minority investments (5) — — — — — (17) (17) (0.01) — Medical device regulations (7) — (11) 0.1 14 0.2 14 11 0.01 21.4 Other (6) 90 — 0.6 90 1.1 90 70 0.05 22.2 Certain tax adjustments, net — — — — — — 17 0.01 — Non-GAAP $ 8,004 $ 2,730 65.9 % $ 1,953 24.4 % $ 1,925 $ 1,592 $ 1.23 17.0 % See description of non-GAAP financial measures contained in the press release dated August 19, 2025. (1) The data in this schedule has been intentionally rounded to the nearest million or $0.01 for EPS figures, and, therefore, may not sum. (2) The Company recognized $45 million of accelerated amortization on certain intangible assets within the Cardiovascular Portfolio. (3) The charges primarily relate to employee termination benefits and facility related and contract termination costs. (4) The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. For the three months ended July 25, 2025, exit of business-related charges primarily relate to the impending separation of the Diabetes business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System. (5) We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. (6) Reflects adjustments to the Company's Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015. (7) The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs. See description of non-GAAP financial measures contained in the press release dated August 19, 2025. (1) The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum. (2) The charges primarily relate to employee termination benefits and facility related and contract termination costs. (3) The charges primarily include changes in fair value of contingent consideration and exit of business-related charges, which primarily relate to the impending separation of the Diabetes business and costs associated with the Company's June 2021 decision to stop the distribution and sale of the Medtronic HVAD System. (4) Reflects adjustments to the Company's Italian payback accruals resulting from the Legislative Decree published by the Italian government on June 30, 2025 for certain prior years since 2015. (5) We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. (Unaudited) Three months ended (in millions) July 25, 2025 July 26, 2024 Operating Activities: Net income $ 1,047 $ 1,049 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 748 662 Provision for credit losses 28 18 Deferred income taxes 167 88 Stock-based compensation 86 83 Other, net 159 (9) Change in operating assets and liabilities, net of acquisitions and divestitures: Accounts receivable, net 288 110 Inventories (373) (217) Accounts payable and accrued liabilities (598) (604) Other operating assets and liabilities (464) (194) Net cash provided by operating activities 1,088 986 Investing Activities: Additions to property, plant, and equipment (504) (520) Purchases of investments (2,100) (1,879) Sales and maturities of investments 2,010 2,157 Other investing activities, net (125) (17) Net cash used in investing activities (719) (259) Financing Activities: Change in current debt obligations, net 649 (624) Issuance of long-term debt — 3,209 Payments on long-term debt (1,162) — Dividends to shareholders (910) (898) Issuance of ordinary shares 95 89 Repurchase of ordinary shares (123) (2,492) Other financing activities, net 70 (15) Net cash used in financing activities (1,381) (731) Effect of exchange rate changes on cash and cash equivalents 67 31 Net change in cash and cash equivalents (945) 27 Cash and cash equivalents at beginning of period 2,218 1,284 Cash and cash equivalents at end of period $ 1,273 $ 1,311 Supplemental Cash Flow Information Cash paid for: Income taxes $ 402 $ 394 Interest 81 119 The data in this schedule has been intentionally rounded to the nearest million, and, therefore, may not sum.
Cision Canada
a few seconds ago
- Cision Canada
Aghanim Unveils Checkout 2.0, Kinetic Framework & More to Power the Future of Game Commerce
Aghanim - a fast-growing fintech organization with over 250 web-based game hubs, built using its innovative Game Hub Builder, is now unveiling the next generation of tools to power direct-to-consumer (DTC) strategy for video games. LOS ANGELES, Aug. 19, 2025 /CNW/ -- Aghanim, the fintech force behind mobile gaming's direct-to-consumer (DTC) revolution, offers the revolutionary LiveOps Builder and Game Hub Builder - marking a substantial leap from low-performing webshops. The LA-based fintech organization creates content-first community websites for mobile games in less than a minute, and with the help of Newton ™, a GenAI-powered co-pilot, now proudly announces its new offerings: Kinetic ™ - A proprietary development framework designed to enable unparalleled customization and control in the creation, maintenance, and continuous optimization of Aghanim-powered game hubs. Blueprints ™ - A set of high-performing web-based liveops campaigns, ready to use under the LiveOps Builder templates, battle-tested on the millions of players visiting Aghanim-powered game hubs. Aghanim Connect - Allows game studios to easily connect their Aghanim-powered entities to third-party tools and services such as PlayFab, AppsFlyer, Adjust, Singular, and many more. Aghanim Checkout 2.0 - Our latest, fastest, and most conversion-optimized checkout technology, tailored to the needs of game studios and unique diverse player habits, in full compliance with the latest developments in the video game industry. Kinetic ™ empowers developers and publishers to build, manage, and evolve richly immersive web experiences through a uniquely modular and extensible architecture. At the core of Kinetic ™ lies a block-based UI system optimized for game-centric interfaces, powered by an adaptive layout engine that ensures responsive rendering across devices and resolutions. The high-powered architecture supports real-time content manipulation and advanced dynamic logic embedding directly into front-end structures, delivering high-performance & data-driven interactivity. Kinetic ™ incorporates a proprietary semantic configuration language engineered for both human readability and artificial intelligence compatibility. This enables the automated generation, deployment, maintenance, and optimization of Aghanim-powered game hubs. Designed to maximize both creative expression and technical precision, Kinetic ™ allows for fine-grained personalization of every website element, enabling live data integration, variable management, and customization. Kinetic ™ is the foundation for delivering visually distinctive, technologically advanced, and operationally agile web-based game hubs - empowering game creators to innovate without compromise. Aghanim's Checkout 2.0 isn't just a product update - it's the culmination of relentless innovation and data-driven refinement. Since its inception, Aghanim has pioneered app-to-web linkouts for mobile games, generating tens of millions of player sessions across its game hubs. Today, we're unleashing the full power of that experience in the form of Checkout 2.0, as a response to the latest developments in the United States, Japan and the European Union related to Apple AppStore and Google Play apps distribution and monetization changes. Using Aghanim's Checkout 2.0, (built on a proprietary fintech stack), each game studio can: Seamlessly link out players from the game to a browser-based checkout Automatically authenticate players with pre-filled carts Incentivize players to make purchases and connect their payment details by offering white-label out-of-the-box loyalty programs and cashback reward point services Support credit cards, Apple Pay, Google Pay, digital wallets, and many more Convert taps into purchases faster than any off-the-shelf payment tool - then seamlessly auto - return players directly back to the game Aghanim's Checkout 2.0 increases net revenue for game studios by up to 220%, while delivering mission-critical marketing insights needed to improve return on marketing investment (ROMI). It is deeply integrated with our proprietary LiveOps Builder™, which enables real-time, programmatic responses to each player's behaviour - whether that means presenting an upsell opportunity after a successful transaction, or capitalising on a failed one (due to insufficient funds) by automatically triggering a time-limited alternative offer priced according to the player's predicted account balance. Whether Aghanim is integrated into an app, dropped in a Discord post, delivered via email, embedded in a social story, or scanned via QR code: Aghanim's Checkout 2.0 - Payment Links meets players where they are, then converts them into paying users - instantly. Aghanim Connect is the foundation of Aghanim's commitment to being a clear open platform - one that actively collaborates with peers and leaders across every sector of the video game industry. Seamlessly connect over 30 pre-integrated tools to your Aghanim-powered stack - simplifying your integration, syncing SKUs, news, and leaderboards, and ensuring data consistency across global marketing campaigns by linking your DTC sales with platforms like PlayFab, AppsFlyer, Adjust, Singular, Google Analytics, Google Tag Manager, Meta Pixel, and more. Blueprints ™ allows studios to discover and easily implement battle-tested web-based monetization liveops campaigns triggered by players visiting Aghanim-powered entities on the individual user level. Programmatically react to players' behaviour on game hub login. Whether they are purchasing virtual items, claiming a daily reward, redeeming coupons, visiting web stores, abandoning carts - Aghanim enables publishers and developers alike to keep full control of the player journey and maximize conversions via constant a/b testing and experimentation - no coding skills required. About Aghanim: Aghanim is an integrated commerce, liveops automation, community engagement, and payments platform for mobile games - founded by a team of former C-level executives from Xsolla. The organization has pioneered app-to-web linkout solutions and now delivers the most seamless app-to-web checkout experience in the market - battle-tested and optimized using tens of millions of data points generated by the millions of users that engage with Aghanim-powered game hubs built on Kinetic ™, the company's proprietary website customization framework.
Globe and Mail
12 minutes ago
- Globe and Mail
Enbridge Announces Conversion Results for Series 15 Preferred Shares
CALGARY, AB, /CNW/ - Enbridge Inc. (TSX: ENB) (NYSE: ENB) (Enbridge) announced today that none of its outstanding Cumulative Redeemable Preference Shares, Series 15 (Series 15 Shares) will be converted into Cumulative Redeemable Preference Shares, Series 16 (Series 16 Shares) on September 1, 2025.
